Swiss Medical Technology Industry 2012

The internationally escalating pressure of costs, pricing and competition, growing regulatory requirements, scarce expert capacities and the strong Franc leave the Swiss medical technology sector faced with enormous challenges. Valuable parts of the supply chain threaten to migrate out of Switzerland. The Swiss Medical Technology Industry 2012 report reveals where the journey leads. The Medical Cluster, Medtech Switzerland and IMS Consulting Group present the results from over 320 firm interviews and reveal possible solutions.

With over 1,600 companies, 51,000 full-time positions, a turnover of around 12.5 billion CHF contributing to 2.1 per cent of the Swiss GDP, and an export volume of nearly 11 billion CHF, the Swiss medical technology industry is still doing well. By international comparisons, Switzerland as a region is still a global "hot spot" for medical technology. Until now, Switzerland has had a great advantage in that the proximity of the entire medtech value chain has allowed the industry to support itself and work together to fuel the growth of the entire Swiss medtech industry. However, circumstances are rapidly changing.

Growth in the single digits - shrinking margins
The 2012 SMTI report reveals an increasing trend of slow growth compared to the last two studies. The average growth expectancy now rests at 5.9 per cent for 2012 and at 6.6 per cent for 2013, or almost half the growth rate seen in previous years. According to the authors of the study, growth will remain in the single-digit figures in the near future. The average growth in the medtech workforce over the last two years continues to be positive at 3 per cent, but still remains lower than expected. For many companies it appears that the golden days are over. "Five to ten years ago the margins amounted to, on average, over 10 per cent, today they come only within the single-digit per cent range," emphasise both authors of the study, Patrick Dümmler, Medtech Switzerland, and Beatus Hofrichter, IMS Consulting Group.

Small firms, especially from the supply industry, suffer the most from growing international pressure due to pricing and competition. The strength of the Swiss franc is named as another of the three greatest challenges for the sector Thus despite the lower limit on the exchange rate, industry export has had to absorb a currency appreciation of 23 % since the beginning of 2010 when compared to the Euro. According to the survey, 81 per cent of all SMTI firms are affected by this problem.

Exchange rate problems intensify foreign investments
To better safeguard against exchange rate fluctuations, 15 per cent of all companies are planning investments over the next three years in production facilities abroad where the economic environment is more favourable (natural hedging). Suppliers and manufacturers will also increasingly procure their outlay and investment goods outside of Switzerland. In addition, more and more Swiss medical technology firms are converting to foreign ownership. In Switzerland the tight budgets in the Swiss healthcare system, administrative expenditures and bureaucracy place increasing strain on the companies as a result of growing regulatory requirements. This all leads to the threat of impending migration of the supply chain. "There is an urgent need for negotiation to prevent the Swiss medical technology ecosystem from breaking apart," the authors warn.

Not only external factors, but also internal structural weaknesses accelerate the trend towards consolidation however. Companies are lacking in management skills and expert knowledge. In particular, marketing, compliance, regulatory affairs and QM specialists are strongly needed.

Forming national clusters and operating pools
In over 86 per cent of all responses, marketing development and market knowledge were considered an important topic, followed by increase in profitability. Currently the sector focuses on commercial and operative excellence. Despite more intense competition, medical technology companies concentrate too little on the strategic development of new business models and marketing channels.

In view of the developments mentioned, and according to the authors of the study, it is high time to act both for the sector and for the region as a whole. The medical technology industry must take on an active role in market consolidation. The authors of the study see potential a solutions in the formation of national clusters and product and/or service pools, within which the suppliers of healthcare services and products develop innovative solutions together to support the Swiss supply chain.

SMTI 2012 report for download:
http://www.medical-cluster.ch/smti

Most Popular Now

SPARK TSL Acquires Sentean Group

SPARK TSL is acquiring Sentean Group, a Dutch company with a complementary background in hospital entertainment and communication, and bringing its Fusion Bedside platform for clinical and patient apps to...

Standing Up for Health Tech and SMEs: Sh…

AS the new chair of the health and social care council at techUK, Shane Tickell talked to Highland Marketing about his determination to support small and innovative companies, by having...

GPT-4 Matches Radiologists in Detecting …

Large language model GPT-4 matched the performance of radiologists in detecting errors in radiology reports, according to research published in Radiology, a journal of the Radiological Society of North America...

ChatGPT Extracts Data for Ischaemic Stro…

In an ischaemic stroke, an artery in the brain is blocked by blood clots and the brain cells can no longer be supplied with blood as a result. Doctors must...

Herefordshire and Worcestershire Health …

Herefordshire and Worcestershire Health and Care NHS Trust has successfully implemented Alcidion's Miya Precision platform to streamline bed management workflow across seven community hospitals in Worcestershire. The trust delivers community...

Experts Propose Specific and Suited Guid…

Current Artificial Intelligence (AI) models for cancer treatment are trained and approved only for specific intended purposes. GMAI models, in contrast, can handle a wide range of medical data including...

A Shortcut for Drug Discovery

For most human proteins, there are no small molecules known to bind them chemically (so called "ligands"). Ligands frequently represent important starting points for drug development but this knowledge gap...

New Horizon Europe Funding Boosts Europe…

The European Commission has announced the launch of new Horizon Europe calls, with a substantial funding pool of over €112 million. These calls are aimed primarily at pioneering projects in...

Cleveland Clinic Study Finds AI can Deve…

Cleveland Clinic researchers developed an artficial intelligence (AI) model that can determine the best combination and timeline to use when prescribing drugs to treat a bacterial infection, based solely on...

New AI-Technology Estimates Brain Age Us…

As people age, their brains do, too. But if a brain ages prematurely, there is potential for age-related diseases such as mild-cognitive impairment, dementia, or Parkinson's disease. If "brain age...

Radboud University Medical Center and Ph…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Radboud University Medical Center have signed a hospital-wide, long-term strategic partnership that delivers the latest patient monitoring...

With Huge Patient Dataset, AI Accurately…

Scientists have designed a new artificial intelligence (AI) model that emulates randomized clinical trials at determining the treatment options most effective at preventing stroke in people with heart disease. The model...